HOME >> BIOLOGY >> NEWS
Staph aureus bacteremia in ESRD patients associated with substantial illness and higher costs

Chicago, Illinois, September 17, 2003 Substantial treatment costs and illness are suffered by end-stage kidney (renal) disease (ESRD) patients who develop Staph aureus blood stream infections (bacteremias), according to new pharmacoeconomic studies presented this week at the 43rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. Moreover, ESRD patients with Staph aureus bacteremia that are caused by bacteria that are resistant to the antibiotic methicillin (MRSA) are at a higher risk of dying and incur higher treatment costs than patients with bacteremias caused by methicillin sensitive Staph aureus (MSSA). The two studies, sponsored by Nabi Biopharmaceuticals, Inc. (Nasdaq: NABI) and executed by Duke University Medical Center, were presented by investigators from Duke University Medical Center and Duke Clinical Research Institute, Durham, NC.

"Staph aureus is the most common cause of serious hospital-acquired infections, including bloodstream infections, and their increased resistance to many different antibiotics is a growing source of concern in the medical community," said Henrik S. Rasmussen, M.D., Ph.D., Nabi Biopharmaceuticals senior vice president, clinical, medical and regulatory affairs. "Despite its clinical significance, the economic impact of Staph aureus bacteremia has not been fully appreciated. The two studies presented at ICAAC clearly describe the clinical outcomes, associated with health care resource utilization and infection-associated costs of Staph aureus bacteremia among a large group of prospectively identified, hemodialysis-dependent patients. The full data from these studies have been submitted for publication."

"Clearly, these studies point out the tremendous challenges that continue to face healthcare professionals trying to manage Staph aureus bacteremias in ESRD patients," continued Dr. Rasmussen. "These results underscore the need for a new approach such as Nabi Biopharmac
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
17-Sep-2003


Page: 1 2 3 4 5

Related biology news :

1. An aspirin a day keeps Staphylococcus aureus away
2. Discovery of iron-acquisition pathway suggests new treatments for drug-resistant Staph. infections
3. The growing Staphylococcus aureus arsenal
4. Surprising role for Staphs toxic shock toxin
5. Nabi experimental vaccine reduced Staph aureus bloodstream infections by nearly 60 percent
6. Staph bacteria are prolific gene swappers, researchers show
7. Experimental Staph Vaccine Broadly Protective In Animal Studies
8. Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Trial shows which brain cancer patients benefit from temozolomide
10. Study of flu patients reveals virus outsmarting key drug
11. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay

Post Your Comments:
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... ... 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised for ... diagnostics industry. BCC Research reveals in its new report that the market drivers of ... a growing need for better diagnostics as part of a molecular diagnostics trend. , ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... July 1, 2015 Isagenix International, a leading ... three Gold, three Silver, and three Bronze Stevie® Awards ... in Chicago this month.The ... business awards program in the U.S. ... strength in developing leaders, cultivating talent, creating a unified ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
Cached News: